Trial Profile
A Phase II Trial of PD-1 Knockout Engineered T Cells for the Treatment of Advanced Lung Adenocarcinoma with PDL-1 high expression progressed after multi-line treatment
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2017
Price :
$35
*
At a glance
- Drugs PD-1 knockout T-cells (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Adverse reactions
- 13 Jan 2017 New trial record